The stock will likely trade near the offer price with a small spread reflecting regulatory and closing risk. Monitor for any competing bids or regulatory developments that could affect the timeline or terms. CRH expects the deal to be accretive to earnings, margin, and cash flow within 12 months post-close.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 23 $144.92entry
- T+1 · 5mo ago −0.40%α −0.35% · $144.34
- T+5 · 5mo ago +0.26%α −1.54% · $145.29
- T+20 · 4mo ago −0.12%α −1.28% · $144.74
- T+60 · 2mo ago +0.37%α −3.59% · $145.45
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CRH (NYSE: CRH) announced a definitive agreement to acquire Arcosa (ACA) for $150 per share in an all-cash transaction, representing a total enterprise value of approximately $8.5 billion. The offer implies a 25% premium to Arcosa's 60-day VWAP and an 11.5x multiple on 2026E Adjusted EBITDA including $175 million in expected run-rate cost synergies. The transaction, unanimously approved by both boards, is expected to close in Q1 2027, subject to Arcosa stockholder and regulatory approvals.
Key Financial Metrics
Key Facts
- CRH to acquire 100% of Arcosa for $150 per share in cash
- Total enterprise value of approximately $8.5 billion
- 25% premium to Arcosa's 60-day trading VWAP as of June 18, 2026
- Acquisition multiple of 11.5x 2026E Adjusted EBITDA, including $175 million in estimated annual run-rate cost synergies by year three
- Transaction expected to close in Q1 2027, subject to Arcosa stockholder and regulatory approvals
- Boards of both companies unanimously approved the transaction
Financial Impact
Arcosa shareholders receive $150 per share in cash, a 25% premium to the 60-day VWAP. The deal values Arcosa at $8.5 billion enterprise value.
Risk Factors
- Failure to obtain Arcosa stockholder approval
- Regulatory approvals not received or delayed
- Potential competing bids or termination of the agreement
- Integration risks and ability to realize $175 million in cost synergies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (ACA), Batch item 1 | 0001104659-26-076360 |
| Document: 0001104659-26-076360-index-headers.html | 0001104659-26-076359 |
| Document: 0001104659-26-076360-index.html | 0001104659-26-076360 |
| Document: 0001104659-26-076360.txt | 0001104659-26-076360 |
| DEFA14A Filing (ACA), Batch item 5 | 0001104659-26-076359 |
| Document: 0001104659-26-076359-index-headers.html | 0001104659-26-076360 |
| Document: 0001104659-26-076359-index.html | 0001104659-26-076360 |
| Document: 0001104659-26-076359.txt | 0001104659-26-076360 |
Track record
16 reports on ACA
3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +17.74% at T+60 after the Jun 5, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 4, 202612d ago Institutional Cluster Bearish 4/10 No price data
- Nov 2, 202614d ago 15-12G Neutral 3/10 No price data
- Oct 23, 202624d ago 25-NSE Mixed 8/10 Entry $149.50 settles Jan 21
- Oct 23, 202624d ago 25-NSE Bullish 7/10 Entry $149.50 settles Jan 21
- Oct 23, 202624d ago 8-K / 25-NSE Mixed 8/10 Entry $149.50 settles Jan 21
- Aug 25, 202611w ago DEFA14A Neutral 3/10 Entry $145.25 settles Nov 18
- Aug 14, 202613w ago Institutional Cluster Mixed 5/10 Entry $145.01 due Nov 10
- Aug 5, 202614w ago DEFA14A Neutral 4/10 Entry $144.89 No price data
- Jun 22, 202621w ago DEFA14A Bullish 7/10 Viewing Entry $144.92 to $145.45 ▲ +0.37% −3.59% vs SPY
- Jun 22, 202621w ago DEFA14A Bullish 7/10 Entry $144.92 to $145.45 ▲ +0.37% −3.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers